The Company provides updated information on its liquidity position through its quarterly reporting.

The Board of Directors and management maintain an ongoing focus on the Company’s financial position and consider financing alternatives as part of normal corporate governance.

As previously communicated, the Company is working to establish a longer-term financing structure to support continued commercialisation and growth. The Board will assess the timing and structure of financing in light of the Company’s operational development.

The Company continues to work actively on the commercial development in England, both within the RTP programme and in dialogue with individual specialist networks.

The ongoing processes involve multiple parties, and progress is therefore dependent on both commercial and structural clarifications with partners.

The Company will update the market when information becomes available that is required to be disclosed in accordance with applicable regulations.

Transactions carried out by former management have previously been disclosed to the market in accordance with applicable regulations. With reference to the stock exchange announcement published on 10 April 2024, it has been communicated that Alf Martin Johansen, through his company NPP Capital, holds shares on behalf of lenders.

As a general rule, the Company does not comment on individual shareholders’ transactions beyond what has been publicly disclosed. Such transactions may have various reasons and do not necessarily reflect the Company’s operational development or outlook.

There is an error in the text of the quarterly report which it is important to clarify.

Cash at the end of Q1 amounted to NOK 73,000, as correctly stated in the balance sheet.

The amount of NOK 2.8 million referred to in the text also includes short-term receivables and therefore does not represent cash and cash equivalents.

The Company regrets that the wording in the report may have caused confusion and will ensure clearer presentation of similar information in future reporting.

There is an error in the text of the quarterly report which it is important to clarify.

Cash at the end of Q1 amounted to NOK 73,000, as correctly stated in the balance sheet.

The amount of NOK 2.8 million referred to in the text also includes short-term receivables and therefore does not represent cash and cash equivalents.

The Company regrets that the wording in the report may have caused confusion and will ensure clearer presentation of similar information in future reporting.

The Company is in dialogue with AstraZeneca regarding the rollout of the severe asthma module in Hull and the associated network of Trusts, which is an established specialist environment for severe asthma. These discussions take place both in connection with, and independently of, the RTP structure.

Any commercial clarifications, including financing structure, remain subject to ongoing discussions and will be communicated when and if agreements are concluded.

The platform is designed to support the full care pathway within specialist care and can also be adapted to different organisational levels and user groups.

The subscription model will apply to all participants in the network and will, in that respect, cover both patients referred for assessment and those receiving biologic treatment.

The Company’s strategy is to standardise the rollout of the solution across markets and collaboration models.

RTP represents a broader, structured rollout pathway and allows for closer collaboration with partners within the RTP programme during implementation. Dialogue with individual networks or Trusts, such as Hull, must be negotiated and resourced directly between Induct, the customer, and any relevant partners.

Operationally, these tracks may overlap, but they differ in how financing and decision-making processes are carried out.

Induct’s ambition is to be a leading provider of tailored digital care pathways and collaboration solutions for healthcare organisations. The Company therefore does not consider this to be an either/or proposition.

Severe asthma is an area where the need for structured workflows, decision support and coordination between clinical environments is clearly demonstrated. The solution has therefore delivered tangible benefits for the Portsmouth team.

The Induct platform has been developed with broader applicability in mind and is not limited to a single pathway or disease.

The Company sees significant potential beyond the severe asthma module, and this is supported technically within the platform.

Induct views “multiple pathways” as a natural and important part of the Company’s long-term strategy - to be a leading provider of tailored digital care pathways and collaboration solutions for healthcare organisations. The platform is built on a generic, modular framework that enables expansion into new clinical pathways without fundamental technological changes.

Within respiratory diseases, where strong competence has already been established through the severe asthma work, adjacent illnesses such as COPD are considered a logical extension.

Induct will continue to develop the product and new pathways in a disciplined manner, focusing on areas where the Company can achieve a strong market position and clear competitive advantages.

Structured and standardised data management is a fundamental prerequisite for scalability and further functionality in digital healthcare solutions.

In healthcare, clinical data is often fragmented across systems and stakeholders, and effective collaboration requires that data can be exchanged, understood and used consistently across organisations and levels of care.

The platform’s approach is therefore to structure key data points and workflows in a way that enables reuse and standardisation across implementations. This is a key factor in scaling the solution across networks and clinical areas without requiring new data structures for each implementation.

A consistent data foundation also supports analytics, decision support and further functional development, including data analytics and AI where relevant. Such capabilities depend on high data quality, interoperability and compliance with regulatory requirements, and will evolve in line with specific needs in each market and collaboration.

The transition from an advertising- based model to a subscription-based model is a central part of the Company’s commercial strategy.

The subscription model is better aligned with how digital solutions are procured and operated in healthcare, enabling predictable costs related to ongoing use and operation of the solution.

In the UK market, the solution may be procured both by individual NHS Trusts and through regional structures such as Integrated Care Boards (ICBs). ICBs are responsible for planning and funding healthcare services across multiple stakeholders. This provides multiple entry points to the market and facilitates broader rollout over time.

In the context of the RTP programme, the Company assumes that different financing models may be applied.

Overall, the Company believes that a subscription-based model is well suited for scaling, as it enables standardisation across networks and provides a basis for more predictable commercialisation over time.

The Company expects to receive revenues related to setup, localisation and implementation during the rollout period. Subscription revenues from individual hospitals, or regions, are expected to commence a few months after the solution has been implemented and handed over to the customer.

The Company will provide further information as and when appropriate.

As communicated in the Q1 2026 report, the Company’s commercial discussions relating to broader rollout in England are aligned with the Respiratory Transformation Partnership (RTP) programme, where AstraZeneca is a key participant. In parallel, discussions relating to a rollout in Hull continue outside the RTP framework.

The correction notice reflects an adjustment to the expected timeline.

The ambition to deliver the severe asthma module across the UK remains unchanged.

The Company is aware that AstraZeneca has previously adjusted its manufacturing and research facility investment plans in the UK.

Based on dialogue in the ongoing processes, it is the Company’s assessment that this has not had a direct impact on the commercial discussions relating to the Company’s solutions.

AstraZeneca’s “Project 50” is an initiative within severe asthma aimed at increasing the number of patients with access to biologic treatment through improved identification, referral and follow-up (50.000 patients by 2028).

Induct is not formally part of this initiative.

However, the Company considers that a digital, structured care pathways is a tool that can support such objectives, by improving coordination, data quality and efficiency in clinical practice and network collaboration.